Search results for "MORBIDITY"

showing 10 items of 986 documents

Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre…

2020

Background and aims: HCV is associated with an increased risk of cardiovascular events (CV). Whether HCV clearance by direct-acting antivirals (DAA) reduces incident CV disease is poorly understood. We investigate whether HCV eradication reduces CV events. Methods: In a prospective multicentre study, 2204 HCV patients (F0–F2:29.5%, F3–F4: 70.5%) were enrolled. Males were 48%, median age was 68 (59–74) years and BMI 25.9 (23.1–28); 24.7% were smokers, 18% had diabetes, 13.2% had cholesterol levels >200 mg/dl and 9.1% took statins, 44% had hypertension. During an overall median follow-up of 28 (24–39) months, incident CV events, such as ischemic heart disease (IHD) and ischemic cerebral st…

Liver CirrhosisMale0301 basic medicineCirrhosisMyocardial IschemiaComorbidityHepacivirusDisease030204 cardiovascular system & hematologyChronic hepatitis Cmedicine.disease_causechemistry.chemical_compound0302 clinical medicineRisk FactorsProspective StudiesIschemic heart disease Ischemic cerebral stroke Chronic hepatitis C CirrhosisIncidenceIncidence (epidemiology)SmokingMiddle AgedViral LoadStrokeItalyHypertensionFemaleCardiology and Cardiovascular MedicineDirect actingmedicine.medical_specialtyIschemic heart diseaseHepatitis C virusHypercholesterolemiaAntiviral Agents03 medical and health sciencesDiabetes mellitusInternal medicineDiabetes MellitusmedicineHumansViremiaAgedCirrhosibusiness.industryCholesterolHepatitis C Chronicmedicine.disease030104 developmental biologychemistryRelative riskIschemic cerebral strokeHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessAtherosclerosis
researchProduct

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. : Triple therapy in HCV geno…

2014

International audience; BACKGROUND & AIMS: We investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection and cirrhosis. METHODS: In the Compassionate Use of Protease Inhibitors in Viral C Cirrhosis study, 511 patients with HCV genotype 1 infection and compensated cirrhosis who did not respond to a prior course of peginterferon and ribavirin (44.3% relapsers or patients with viral breakthrough, 44.8% partial responders, and 8.0% null responders) were given either telaprevir (n = 299) or boceprevir (n = 212) for 48 weeks. We assessed percentages of patients with sustained viral respo…

Liver CirrhosisMaleCirrhosisComorbidityHepacivirusmedicine.disease_causeGastroenterologyPolyethylene GlycolsTelaprevirCohort Studieschemistry.chemical_compound0302 clinical medicinePegylated interferonboceprevirProspective StudiesTreatment FailureAged 80 and overGastroenterologyMiddle AgedRecombinant Proteins3. Good healthTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyOligopeptidesmedicine.drugAdultmedicine.medical_specialtyGenotypeProlineHepatitis C virusAntiviral Agents03 medical and health sciencesBoceprevirInternal medicineRibavirinmedicinechronic hepatitis CHumanstelaprevirAdverse effect[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyAgedHepatologybusiness.industrycirrhosisRibavirinInterferon-alphaOdds ratioHepatitis C Chronicmedicine.diseasechemistryMultivariate AnalysisImmunologybusinessFollow-Up StudiesGastroenterology
researchProduct

Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study

2017

Background and aims Blood lysosomal acid lipase (LAL) is reduced in non-alcoholic steatohepatitis, which is the major cause of cryptogenic cirrhosis (CC); few data on LAL activity in CC do exist. We investigated LAL activity in a cohort of patients with liver cirrhosis. Methods This is a multicentre cohort study including 274 patients with liver cirrhosis of different aetiology from 19 centres of Internal Medicine, Gastroenterology and Hepatology distributed throughout Italy. Blood LAL activity (nmol/spot/h) was measured with dried blood spot extracts using Lalistat 2. Results Overall, 133 patients had CC, and 141 patients had cirrhosis by other causes (61 viral, 53 alcoholic, 20 alcoholic …

Liver CirrhosisMaleCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; PathogenesisCirrhosisCryptogenic cirrhosisCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Cardiology and Cardiovascular MedicineComorbidityPathogenesisLysosonal acid lipase; non-alcoolic fatty liver disease; cirrhosis030204 cardiovascular system & hematologyGastroenterologyLiver disease0302 clinical medicineModel for End-Stage Liver DiseasePathogenesiRisk FactorsPrevalenceProspective cohort studyMultivariate AnalysiSettore MED/12 - GastroenterologiaMiddle AgedItalyCohortLinear Model030211 gastroenterology & hepatologyFemaleCardiology and Cardiovascular MedicineLiver diseaseHumanmedicine.medical_specialtyLiver CirrhosiDown-Regulation03 medical and health sciencesInternal medicineCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Aged; Biomarkers; Chi-Square Distribution; Comorbidity; Cross-Sectional Studies; Down-Regulation; Dried Blood Spot Testing; Female; Humans; Italy; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Platelet Count; Prevalence; Risk Factors; Sterol EsterasemedicineLysosonal acid lipaseHumansnon-alcoolic fatty liver diseaseAgedCross-Sectional StudieChi-Square Distributionbusiness.industryPlatelet CountcirrhosisRisk FactorBiomarkerCholesterol ester storage diseaseHepatologySterol Esterasemedicine.diseaseCross-Sectional StudiesMultivariate AnalysisLysosomal acid lipaseLinear ModelsDried Blood Spot TestingSteatohepatitisbusinessCryptogenic cirrhosiBiomarkers
researchProduct

Oral lichen planus, hepatitis C virus, and HIV: no association in a cohort study from an area of high hepatitis C virus endemicity

2004

Abstract Objectives We sought to assess the age-specific prevalence of oral lichen planus (OLP) in Mediterranean patients with chronic hepatitis C virus (HCV) and to evaluate the features of OLP in relation to sex, smoking, HCV genotype, HIV-1 coinfection, and antiviral treatments. Methods In all, 178 anti-HCV-positive adults (60 women and 118 men; age range 20-66 years) recruited from two cohorts (104 HIV-negative patients and 74 patients with HIV coinfection) underwent oral examination. Results Overall prevalence of OLP was 2.8% (5 of 178) (male/female ratio 0.2; odds ratio=0.119; 95% confidence interval=0.013-1.106), only among HIV-negative participants, always in the reticular pattern, …

Liver CirrhosisMaleHepacivirusHIV Infectionsclinical-featureComorbidityHepacivirusmedicine.disease_causeCohort Studieschemistry.chemical_compoundPrevalenceMedicineExtrahepatic manifestationbiologySmokingvirus diseasesMiddle AgedHepatitis CCoinfectionFemalegeneral-populationmedicine.drugAdultmedicine.medical_specialtyGenotypeHepatitis C virushuman-immunodeficiency-viruDermatologyHCV hyperendemic areaAntiviral AgentsFlaviviridaeAge Distributionstomatognathic systemInternal medicineHumansInterferon alfaAgedbusiness.industryRibavirinChronic active hepatitiOdds ratiomedicine.diseasebiology.organism_classificationstomatognathic diseaseschemistrypositive patientsImmunologynegative patientliver-diseaseOral lichen planusinterferon therapybusinessLichen Planus Oral
researchProduct

Potentially inappropriate use of furosemide in a very elderly population: An observational study

2017

International audience; ObjectiveLittle is known about furosemide prescription modalities in elderly people. We describe furosemide prescription in ambulatory elderly patients.MethodsAll patients aged over 80 years, affiliated to Mutualité Sociale Agricole de Bourgogne, a French regional health insurance plan, with a medical prescription delivered in March 2015, were retrospectively included.ResultsAmong 15 141 patients with a median age of 86 years, comprising 61.3% of women, 3937 patients (26%) had a prescription for furosemide. Severe heart failure was the most common chronic comorbidity (27.7%). Furosemide was considered a long-term therapy for almost all patients (98.7% with prescripti…

Liver CirrhosisMalePediatricsmedicine.medical_specialtyAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsInappropriate Prescribing[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology030204 cardiovascular system & hematologyDrug PrescriptionsNephropathy03 medical and health sciences0302 clinical medicineFurosemidemedicineHumans030212 general & internal medicineMedical prescriptionRenal Insufficiency ChronicDiureticsRetrospective StudiesAged 80 and overHeart Failurebusiness.industryAge FactorsFurosemideRetrospective cohort studyGeneral Medicinemedicine.diseaseComorbidityHeart failureAmbulatoryObservational studyFemalebusinessmedicine.drug
researchProduct

Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy

2020

Abstract Background and aims Nonalcoholic steatohepatitis (NASH) may progress to advanced liver disease (AdvLD). This study characterized comorbidities, healthcare resource utilization (HCRU) and associated costs among hospitalized patients with AdvLD due to NASH in Italy. Methods and results Adult nonalcoholic fatty liver disease (NAFLD)/NASH patients from 2011 to 2017 were identified from administrative databases of Italian local health units using ICD-9-CM codes. Development of compensated cirrhosis (CC), decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC), or liver transplant (LT) was identified using first diagnosis date for each severity cohort (index-date). Patients progres…

Liver CirrhosisMaleTime FactorsCirrhosisDatabases FactualEndocrinology Diabetes and MetabolismMedicine (miscellaneous)ComorbidityHospital Cost030204 cardiovascular system & hematologyLiver diseasePatient Admission0302 clinical medicineRetrospective StudieNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseAmbulatory CarePrevalenceMedicineHospital Costseducation.field_of_studyDrug CostNutrition and DieteticsLiver NeoplasmsNASHMiddle AgedPrognosisItalyLiver NeoplasmHepatocellular carcinomaCohortDisease ProgressionHealth ResourcesFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularTime FactorAdolescentCostPrognosiLiver CirrhosiPopulation030209 endocrinology & metabolismPharmacyDrug CostsYoung Adult03 medical and health sciencesNAFLDInternal medicineHumanseducationAgedRetrospective StudiesHealth Resourcebusiness.industryRisk Factormedicine.diseaseComorbiditydigestive system diseasesLiver TransplantationHCRUbusinessAdministrative Claims HealthcareNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study

2015

EA Pôle MERS Hors CT hors EJ; International audience; Background & Aims: To compare the management of chronic hepatitis B (CHB) and its evolution over time in currently followed HIV-positive and HIV-negative patients. Methods: A total of 709 consecutive patients with past or present positive HBs antigenemia seen in October 2012 in 19 French participating centres were included. The data were retrospectively collected from the first visit onwards through standardized questionnaires. Results: Chronic hepatitis B was less often assessed in the 299 HIV-positive patients, who were older, more likely to be male, excessive alcohol drinkers and HBe antigen-, HCV- and HDV-positive. They were also fol…

Liver CirrhosisMale[SDE] Environmental SciencesCirrhosis[SDV]Life Sciences [q-bio]HIV InfectionsComorbidityCohort Studies0302 clinical medicineReference ValuesHIV SeropositivityHBV[SDV.BV] Life Sciences [q-bio]/Vegetal Biology030212 general & internal medicineHIV SeronegativityLiver NeoplasmsLamivudinevirus diseasesEntecavirhepatocellular carcinomaMiddle Aged3. Good health[SDV] Life Sciences [q-bio]Treatment OutcomeLamivudineHepatocellular carcinoma[SDE]Environmental SciencesDisease ProgressionFemale030211 gastroenterology & hepatologyFranceCohort studymedicine.drugAdultmedicine.medical_specialtyGuanineAntiviral AgentsRisk AssessmentStatistics Nonparametric03 medical and health sciencesHepatitis B ChronicHIV SeronegativityInternal medicinemedicineHumans[SDV.BV]Life Sciences [q-bio]/Vegetal BiologySurvival analysisRetrospective StudiesHepatitis B Surface AntigensHepatologybusiness.industrycirrhosisHIVmedicine.diseaseSurvival AnalysisComorbiditytenofovirLogistic ModelsMultivariate AnalysisImmunologybusinessentecavir
researchProduct

Should cirrhosis change our attitude towards treating non-hepatic cancer?

2011

Cirrhosis is a major cause of morbidity and mortality and is the end stage of any chronic liver disease. Cancer, a leading cause of death worldwide, is a growing global health issue. There are limited data in the literature on the incidence, prevalence and management of non-hepatic cancers (NHC) in cirrhotic patients. The aim of this brief review was to underline the main concerns, pitfalls and warnings regarding practice for these patients. Survival of patients with compensated cirrhosis is significantly longer than that of decompensated cirrhosis and patients with NHC and in Child-Pugh class C should not be candidates for cytotoxic chemotherapy. It is important before starting cytotoxic c…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisAntineoplastic AgentsComorbidityChronic liver diseaseGastroenterologyLiver diseaseInternal medicineCause of DeathNeoplasmsmedicineHumansIntensive care medicineSurvival rateCause of deathHepatologybusiness.industryPatient SelectionCancerProfessional Practicemedicine.diseasechemotherapy – cirrhosis – hepatotoxicity – non-hepatic cancerClinical trialSurvival RateClinical Trials Phase III as TopicPortal hypertensionFemaleChemical and Drug Induced Liver InjurybusinessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation.

2018

Nonalcoholic steatohepatitis (NASH)-related cirrhosis has become one of the most common indications for liver transplantation (LT), particularly in candidates older than 65 years. Typically, NASH candidates have concurrent obesity, metabolic, and cardiovascular risks, which directly impact patient evaluation and selection, waitlist morbidity and mortality, and eventually posttransplant outcomes. The purpose of these guidelines is to highlight specific features commonly observed in NASH candidates and strategies to optimize pretransplant evaluation and waitlist survival. More specifically, the working group addressed the following clinically relevant questions providing recommendations based…

Liver Cirrhosismedicine.medical_specialtyCirrhosisConsensusTime FactorsTissue and Organ ProcurementWaiting Listsmedicine.medical_treatmentConsensus Development Conferences as TopicBariatric SurgeryComorbidityLiver transplantationEnd Stage Liver DiseaseLiver diseaseNon-alcoholic Fatty Liver DiseaseDiabetes mellitusmedicineHumansObesityIntensive care medicineTransplantationbusiness.industrymedicine.diseaseComorbidityLiver TransplantationNatural historyTreatment OutcomeCardiovascular DiseasesEtiologybusinessDyslipidemiaTransplantation
researchProduct

Morphological and Postural Changes in the Foot during Pregnancy and Puerperium: A Longitudinal Study

2021

The aim of this study is to observe the morphological and postural changes to the foot that take place during pregnancy and the puerperium. Method: In this descriptive, observational, longitudinal study, we analysed 23 pregnant women, with particular attention to morphological and postural aspects of the foot, at three time points during and after pregnancy: in weeks 9–13 of gestation, weeks 32–35 of gestation and weeks 4–6 after delivery. The parameters considered were changes in foot length, the Foot Posture Index (FPI) and the Hernández Corvo Index, which were analysed using a pedigraph and taking into account the Body Mass Index (BMI). The same procedure was conducted in each review. Re…

Longitudinal study:Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Postpartum Period [Medical Subject Headings]Health Toxicology and MutagenesisPregnancy puerperiumlcsh:MedicineFoot posture index:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]pedograph0302 clinical medicinePregnancyLongitudinal Studies:Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Pregnancy Trimesters::Pregnancy Trimester Third [Medical Subject Headings]reproductive and urinary physiology:Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Reproductive Physiological Processes::Reproduction::Pregnancy [Medical Subject Headings]ObstetricsIncidence (epidemiology)Postpartum PeriodPostpartum periodfoot posture indexPeriodo pospartoGestationFemalepregnancy puerperiumFoot (unit)medicine.medical_specialty:Persons::Persons::Women::Pregnant Women [Medical Subject Headings]EmbarazoPregnancy Trimester ThirdPosture:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings]Article03 medical and health sciences:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Incidence [Medical Subject Headings]medicine.artery:Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Musculoskeletal Physiological Phenomena::Posture [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies [Medical Subject Headings]medicineHumansPronationPregnancyPedographbusiness.industryFootlcsh:RPublic Health Environmental and Occupational HealthPie030229 sport sciencesmedicine.diseasePronaciónPlantar arch:Check Tags::Female [Medical Subject Headings]:Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Musculoskeletal Physiological Phenomena::Musculoskeletal Physiological Processes::Movement::Motor Activity::Pronation [Medical Subject Headings]foot:Anatomy::Body Regions::Extremities::Lower Extremity::Foot [Medical Subject Headings]businessBody mass index030217 neurology & neurosurgeryPostpartum period
researchProduct